AbbVievs.Merck & Co.
ABBV vs MRK · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 1.3× larger than Merck & Co. by market cap; AbbVie trades at the lower P/E (70.2 vs 103.9); year to date, Merck & Co. leads (+43.1% vs +15.8%).
Side by side
| ABBV | MRK | |
|---|---|---|
| Market cap | $443B | $330B |
| Price | $265.79 | $156.45 |
| Today | +0.5% | +3.8% |
| Return YTD | +15.8% | +43.1% |
| Return 1Y | +25.6% | +72.4% |
| P/E | 70.2 | 103.9 |
| P/S | 6.9 | 5.0 |
| P/B | 312.1 | 7.2 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →Merck & Co.MRK
Keytruda is the centre of the oncology business, which sits next to a substantial vaccines portfolio. Animal health forms a third division.
Full MRK profile →More ABBV & MRK comparisons
Other head-to-heads in the Big pharma segment.
See where ABBV and MRK sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →